HYGROTON
LOE ApproachingNDAORALTABLETPriority Review
Approved
Apr 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYGROTON is an oral tablet small-molecule drug approved in 1960 as an NDA by Sanofi. The specific indication and mechanism of action are not publicly detailed in available data, but the product represents a legacy therapeutic agent with nearly 65 years of clinical use.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on managed decline and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYGROTON offers limited career growth potential as the product is in its final commercial lifecycle phase with no linked job openings. This role is best suited for professionals managing legacy portfolios or seeking stable, low-complexity therapeutic maintenance positions rather than high-impact launch or innovation careers.
Brand ManagerProduct Manager
Worked on HYGROTON at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.